Scientists at the Massachusetts hospital announced the creation and development of an experimental vaccine AACOVID. It has a gene base and has already been named a new candidate for a potential fight against coronavirus. The drug was developed in the laboratory by Dr. med. Luke H. Vandenberg. Now it has been assigned the status of preclinical development, and by the end of this year, it is planned to conduct the first human vaccine tests.
The authors of the development call AACOVID a unique gene-based vaccination strategy that uses an adeno-associated viral vector (AAV), a clinically established gene transfer technology that uses the properties of a harmless viral carrier. This technology has been widely used in the field of gene therapy.
Modern medicine has sufficient experience and the ability to achieve success in this direction: only in recent years, two drugs based on genes have been approved, which indicates the effectiveness of AAV. A potential vaccine is supposed to be administered intramuscularly.
Now, animal tests are being carried out, and initial production work on the release of the vaccine is being organized in parallel. Based on the results of preclinical studies, the clinical phase of patient trials will be conducted. Currently, around the world, about five types of vaccines are being developed.
But AAV can have clear advantages due to adaptability and the ability to create a useful immune response in the human body. The authors of the development said that AAV is one of the safest gene delivery technologies to strengthen immunity against COVID-19, and for this only one injection will be enough.
In a crisis, scientists are using the power of molecular biology to develop a vaccine in a record few weeks. And soon, accurate clinical studies will be required to help establish the safety and effectiveness of the new approach to getting rid of coronavirus.